| atezolizumab based treatment | pembrolizumab based treatment |
| atezolizumab plus carboplatin plus nab-paclitaxel | atezolizumab plus carboplatin plus paclitaxel | pembrolizumab plus SoC |
squamous cell - mNSCLC - L1 | | | |
squamous - mNSCLC - L1 - all population 4 | | | |
squamous - mNSCLC - L1 - PDL1 positive | | | |
squamous - mNSCLC - L1 - Wild Type (WT) | | | |